

# NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

## HEALTH TECHNOLOGY APPRAISAL PROGRAMME

### Equality impact assessment – Scoping

#### STA - Galcanezumab for preventing migraine

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

The British Association for the Study of Headache:

*Women (22%) are affected three times more than men (8%), therefore any recommendation has more impact on the female gender.*

*Migraine is more common in the working age group and any decision on treatment is likely to impact more on the working population.*

The Migraine Trust:

*Migraine can be classed as a disability under the Equality Act 2010*

*Women are three times more likely to be affected by migraine and most common in people of working age. Therefore women who already face inequality in the work place are further disadvantaged by migraine.*

*The 2014 Headache Services report by the APPG on Primary Headache Disorders found that patients in England have non-equivocal access to specialist headache clinics and face barriers accessing appropriate and recommended treatments.*

*If Galcanezumab becomes available via a NICE recommendation, it should be more equitable in availability and access.*

2. What is the preliminary view as to what extent these potential equality issues need addressing by the committee?

Prevalence of condition across genders is not expected to be an equality issue that can be addressed in a technology appraisal.

Migraines as a disability can be considered by the committee, if appropriate, at the time of the appraisal.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

No

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?

No

**Approved by Associate Director (name):** Jasdeep Hayre

**Date:** 12/11/2019